Sign Up Today and Learn More About HeartFlow Stock
Invest in or calculate the value of your shares in HeartFlow or other pre-IPO companies through EquityZen's platform.
HeartFlow Stock (HEFL)
Medical Technology Company
HeartFlow is a medical technology company that provides non-invasive coronary artery disease detection services. The company's main product is HeartFlow FFRCT Analysis, which aims to help a physician evaluate whether a patient has significant coronary artery disease. HeartFlow FFRCT Analysis uses a CT scan that is ordered by a physician to generated a 3D model of the patient's coronary arteries. The analysis aims to calculate the amount of blockage in the arteries and the limited blood flow.
About HeartFlow Stock
Founded
2007
Headquarters
Redwood City, CA, US
Total Funding
756M
Industries
Software, Data and Analytics, Science and Engineering
HeartFlow is a medical technology company that provides non-invasive coronary artery disease detection services. The company's main product is HeartFlow FFRÂ Analysis, which aims to help a physician evaluate whether a patient has significant coronary artery disease. HeartFlow FFRCT Analysis uses a CT scan ordered by a physician to generate a 3D model of the patient's coronary arteries. The analysis aims to calculate the amount of blockage in the arteries and the limited blood flow. The HeartFlow FFRCT Analysis is commercially available in the United States, Canada, Europe, and Japan.Â
Christopher K. Zarins and Charles Anthony Taylor founded Cardiovascular Simulation in 2007 which became HeartFlow in May 2009. The company is headquartered in Redwood City, California. Notable investors include Panorama Point Partners, Capricorn Investment Group, and Baillie Gifford.
HeartFlow Press Mentions
Stay in the know about the latest news on HeartFlow
Heartflow to Showcase Landmark DECIDE Data at SCCT 2025, Advancing AI-Driven Care for Coronary Artery Disease
globenewswire • Jun 30, 2025
In-Depth Analysis Of The Global Digital Health For Cardiovascular Market: Key Drivers, Trends, Growth Opportunities
einpresswire • Jun 16, 2025
Global Cardiovascular Digital Solutions Market to Surpass $140 Billion by 2030, Driven by AI and Remote Monitoring
pharmiweb • Jun 11, 2025
Futuristic 3D heart scans save NHS nearly ÂŁ10m since rollout
telegraph • May 07, 2025
New Analysis Published in Nature Medicine Demonstrates Advantages of Nationwide Coronary CTA Strategy with Heartflow FFRCT in Over 90,000 Patients with Coronary Artery Disease
globenewswire • May 06, 2025
Investors in HeartFlow
Discover investors in HeartFlow stock and explore their portfolio companies
HeartFlow Management
Leadership team at HeartFlow
Chief Executive Officer
John Farquhar
Chief Scientific Officer
Charles Anthony Taylor
Join now and verify your accreditation status to gain access to:
- HeartFlow Current Valuation
- HeartFlow Stock Price
- HeartFlow Management
- Available deals in HeartFlow and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- HeartFlow Cap Table and Funding History by Share Class and Liquidity Preferences
- HeartFlow Revenue and Financials
- HeartFlow Highlights
- HeartFlow Business Model
- HeartFlow Risk Factors
- HeartFlow Research Report from SACRA Research
HeartFlow Key Facts
- Heartflow says that it is dedicated to advancing innovation in coronary care and has developed its own proprietary non-invasive diagnostic technology that is considered to be the first non-invasive device that can be used to diagnose coronary artery disease. This technology has had a measurable impact as it has treated over 400,000 patients and served over 1,400 institutions. Heartflow reportedly has a mission to make its solutions even more widely available to an increasingly diverse patient population worldwide. This creates an opportunity to become the market leader in coronary artery disease (CAD) management.
- In February 2025, Heartflow introduced its new brand identity which the company believes will reflect its focus on delivering clarity, precision, and confidence in the prevention, diagnosis, and treatment of CAD. This new brand identity also reflects input collected from Heartflow customers and cardiovascular community stakeholders showcasing Heartflow's commitment to building customer loyalty which may contribute to the company's long-term success.
- Heartflow has maintained strong financial backing, with its most recent funding round in 2023 of $215 million led by Bain Capital Life Sciences, indicating strong investor confidence. Heartflow announced plans in January 2025 for a initial public offering which is another bullish sign for the company as it prepares for its next stage of growth, generating increased visibility and credibility for its products.
- As Heartflow prepares for a potential IPO, the company may face significant operational and financial scrutiny. Any volatility in the markets can affect investor sentiment and can impact the success of the offering, potentially impacting the company's valuation and future growth plans. In the past few years, high interest rates and poor performances of several medical technology companies that listed during the pandemic led public investors to carry a negative sentiment towards medical device makers, and this could impact Heartflow's IPO.
- The global AI in medical diagnostics market is highly concentrated amongst large players. The top ten competitors in the market make up 56.02% of the total market, with Heartflow capturing 2.5% of market share. Heartflow must continuously innovate in order to maintain a competitive edge or risk losing market share.
- Heartflow is dependent on the Centers for Medicare and Medicaid Services (CMS) in securing reimbursements for its customers and thereby providing its technology to a wider range of patients. Any changes in reimbursement policies or delays in securing necessary approvals could impact the company's growth prospects and financial situation.
Trading HeartFlow Stock
How to invest in HeartFlow stock?
Accredited investors can buy pre-IPO stock in companies like HeartFlow through EquityZen funds. These investments are made available by existing HeartFlow shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell HeartFlow stock?
Shareholders can sell their HeartFlow stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
